Trial reportBritish journal of cancer2004
Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma.
Trial report in British journal of cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Journal of neuro-oncology · 2014Guideline
- Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial.Nature communications · 2026Trial
- Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.Journal of neuro-oncology · 2011Trial
- Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors.Journal of neuro-oncology · 2007Trial
- Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors.Journal of neuro-oncology · 2006Trial
- Focused Ultrasound-Mediated Blood-Brain Barrier Opening Increases Delivery and Efficacy of Etoposide for Glioblastoma Treatment.International journal of radiation oncology, biology, physics · 2021Article
- Article
- A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma.Journal of clinical medicine · 2019Article
- Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?Journal of neuro-oncology · 2018Article
- Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients.Radiation oncology (London, England) · 2014Article
- Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma.Neuro-oncology · 2014Article
- State of the art and perspectives in the treatment of glioblastoma.CNS oncology · 2012Review
- Constitutive Notch2 signaling in neural stem cells promotes tumorigenic features and astroglial lineage entry.Cell death & disease · 2012Article
- An evaluation of the safety and feasibility of convection-enhanced delivery of carboplatin into the white matter as a potential treatment for high-grade glioma.Journal of neuro-oncology · 2012Article
- Article
- Etoposide-mediated glioblastoma cell death: dependent or independent on the expression of its target, topoisomerase II alpha?Journal of cancer research and clinical oncology · 2011Article
- Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.Core evidence · 2010Article
- Canadian recommendations for the treatment of glioblastoma multiforme.Current oncology (Toronto, Ont.) · 2007Article
- Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay.Neuro-oncology advancesArticle
- Bevacizumab alternating chemotherapy for improving the survival of patients with recurrent high-grade glioma.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present the results of a phase II trial of carboplatin and etoposide (CE) combination as first-line chemotherapy in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) after surgery and radiotherapy. We assess the activity and the tolerability of this combination. 30 patients with GBM (25) and AA (5) were treated with VP-16 (etoposide) 120 mg m(-2) and CBCDA (carboplatin) 100 mg m(-2) for 3 days every 4 weeks. Moreover, we performed a retrospective analysis of topoisomerase IIalpha gene status using chromogenic in situ hybridisation. The median age was 54 years (21-73 years); Eastern Cooperative Oncology Group performance score was 0-1 in 25 patients and 2 in five patients. All patients had been previously treated with surgical resection (21 radical resections) followed by radiation therapy (40-60 Gy). We observed six (20%) complete responses, three (10%) partial responses and 12 (40%) stable diseases, with a response rate of 30%. The median time to progression was 4 months, while progression-free survival at 6 months was 33.3%. The median survival time was 10 months. Neutropenia occurred in 9 patients: four patients had grade 4, two patients grade 3 and three patients grade 2. In the conclusion of this clinical trial, the CE combination has shown activity in recurrent GBM and AA, with a good toxicity profile. Alterations in the copy number of topoisomerase IIalpha gene seem to be a rare event and in our series do not influence response to the CE combination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.